Prostate Cancer | Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Prostate Cancer

published 5 months ago by Dr Neil Love

Featuring perspectives from Drs Emmanuel S Antonarakis and Andrew J Armstrong on the following topics: Introduction (0:00) When should postprostatectomy radiation therapy generally be recommended? (2:45) When should the oral GnRH receptor antagonist relugolix be recommended if it were available? (4:17) When should ADT for PSA-only relapse (M0) after local therapy be recommended? (9:26) When should an antiandrogen agent be added to ADT for castration-resistant M0 prostate cancer? (14:04) When do you use prostate-directed local therapy for mHSPC? (22:19) When do you add an antiandrogen agent, abiraterone or docetaxel, to ADT for mHSPC? (Selection of agent) (24:13) How do you generally approach the selection of endocrine treatment versus chemotherapy after first-line endocrine therapy for mCRPC? (31:58) How do you generally approach the use of radium-223 for mCRPC? (34:25) How do you generally approach the use of PARP inhibitors for mCRPC? (37:07) What is known about PSMA-targeted treatment and imaging in prostate cancer? (54:05) What is known about TMPRSS2 and COVID-19? (58:19) CME information and select publications

more episodes from Research To Practice | Oncology Videos